Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

scistats 217 posts  |  Last Activity: 1 hour 55 minutes ago Member since: Apr 5, 2009
  • scistats scistats Apr 17, 2016 10:00 PM Flag

    "A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment"

    Sentiment: Strong Buy

  • This study is conducted over two phases. The pilot phase of this trial is closed. The expansion phase of this trial is currently open to enrollment. Expansion Phase: The expansion will enroll patients with advanced metastatic breast cancer into three cohorts:
    Cohort 1: ER and/or PR-positive breast cancer
    Cohort 2: TNBC
    Cohort 3: BC with active brain metastasis
    Estimated Study Completion Date: October 2017

    Sentiment: Strong Buy

  • "21. A method of treating a urea cycle disorder comprising administering to a subject suffering from or susceptible to a urea cycle disorder, a composition comprising an mRNA encoding an enzyme, encapsulated within a liposome; wherein the enzyme is selected from ornithine transcarbamylase (OTC), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase 1 (ASS1) argininosuccinate lyase (ASL), or arginase (ARG)."

    Sentiment: Strong Buy

  • Reply to

    Shareholder value

    by pentiumpwr Apr 16, 2016 4:32 PM
    scistats scistats Apr 16, 2016 5:52 PM Flag

    This goes back to 2013.
    How exactly are they springing it on us?

    "the Holders will convert the Company’s 4.50% Convertible Senior Notes due 2020 (the “Notes ”) into shares of common stock of the Company, par value $0.01 per share (the “Common Stock ”) pursuant to the provisions of the Base Indenture, dated as of July 17, 2013"

    Sentiment: Strong Buy

  • scistats scistats Apr 16, 2016 5:30 PM Flag

    He is the Nobel Prize winner for super high resolution fluorescent microscope laser technology used to break the Abbe diffraction limit. He worked with Leica to commercialize this technology, just as an example that Leica is at the forefront and a good partner for Merrimack.

    Sentiment: Strong Buy

  • I now proclaim, despite my original taut virility for MACK and in-depth provocative due diligence, I have entered into a soon to be lucrative short downward dog position. The savvy investor is agile and position fluid.

    I have also officially terminated Sir Mulroy. I founded this enterprise as its first angel investor, so forgive me for not asking for permission as I know better than anyone because I invested here first. Basically everyone else is an idiot because I was first. Does that make sense? Ahhh, anyway.

    I return now only to expose the current position of my goods. Having proclaimed this, good day sirs.
    (any sarcasm detected is purely intended)

    Sentiment: Strong Sell

  • As a single agent, imetelstat works for ~35% of myelofibrosis patients.

    Janssen will soon make available a patient-pairing diagnostic kit to be used to identify:
    Which patients are likely to respond to imetelstat

    "We develop both companion diagnostics (diagnostic tests that are indicated in a drug’s prescribing information and required for its safe and effective use) and complementary diagnostics (diagnostic tests that may be in the drug’s prescribing information, but are used to assess disease state and aid in managing a person’s illness)."

    Sentiment: Strong Buy

  • After further review thanks to Italian30_2000, the notorious "Conversion Agreements" appear to have been executed competently.

    Yet, Te_st is still seconding guessing Dr. Al-Wakeel. Te_st, I cut the ribbon for this company (sarcastic) and have been investing in MACK since everyone on this board was is diapers, even before it changed its name. So I will tell everyone when Mulroy should be fired...

    Now we are working with Leica...Stefan Hell ring a bell?

    Sentiment: Strong Buy

  • Reply to

    Colaberation News?

    by nightguil Apr 14, 2016 4:57 PM
    scistats scistats Apr 14, 2016 5:02 PM Flag

    If Leica Bond can i.d. who 121 works for, then yes, it would be a big deal but not until then.

    1 mo? Better move on to scratch offs at the local 7-11. Patience! Buffett says patience! At least avoid the short term capital gains.

    Sentiment: Strong Buy

  • scistats by scistats Apr 14, 2016 4:56 PM Flag

    Merrimack's new friend.
    Awwwww, so sweet!

    Sentiment: Strong Buy

  • Reply to

    Dilution Time- Conversion

    by spec_59 Apr 14, 2016 9:21 AM
    scistats scistats Apr 14, 2016 10:20 AM Flag

    These are Hercules Technology Growth Capital, Inc. notes?

  • Reply to

    Athersys Team in Japan - Met with PMDA

    by wall_street_titan Apr 14, 2016 6:55 AM
    scistats scistats Apr 14, 2016 9:33 AM Flag

    Something is going to happen here with ATHX.
    Lots of irons in the fire from UK to Japan.
    I still want to see Multistem for TB ASAP. The leaders in the field have already pointed Athersys in this direction with their publications.

    Sentiment: Strong Buy

  • scistats scistats Apr 14, 2016 9:27 AM Flag

    Nice to hear the team is staying on top of things.
    Multistem for antibiotic resistant Neisseria gonorrhoeae.

    Sentiment: Strong Buy

  • Reply to

    Athersys Team in Japan - Met with PMDA

    by wall_street_titan Apr 14, 2016 6:55 AM
    scistats scistats Apr 14, 2016 8:48 AM Flag

    This alone would be enough for big pharma to buy Athersys for 20 PPS if they want it cheap. Once ARDS is confirmed with any evidence....

    Sentiment: Strong Buy

  • Reply to

    Athersys Team in Japan - Met with PMDA

    by wall_street_titan Apr 14, 2016 6:55 AM
    scistats scistats Apr 14, 2016 8:43 AM Flag

    What about news out of the UK for the Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome?
    This study is currently recruiting participants, and the outcome should be immediately obvious.
    Per Mayo Clinic, "usually develops within a few hours to a few days after the original disease or trauma. Many people who develop ARDS don't survive."
    Breaking news should be coming from Geoff Bellingan, MD University College London Hospital.

    Sentiment: Strong Buy

  • Reply to

    Pre market

    by stocktock11 Apr 14, 2016 8:16 AM
    scistats scistats Apr 14, 2016 8:38 AM Flag

    Sold what? They are all buys?

    06:48 $ 2.37 Low 1,000
    06:48 $ 2.37 Low 1,000
    06:48 $ 2.37 Low 2,500
    06:48 $ 2.37 Low 4,200
    06:48 $ 2.37 Low 700
    06:47 $ 2.61 High 9,400

    Sentiment: Strong Buy

  • scistats scistats Apr 13, 2016 11:30 PM Flag

    Purpose
    This is a single arm pilot study of 64Cu-MM-302 and unlabeled MM-302 in combination with trastuzumab in 10 patients with advanced HER2+ cancer with new or progressive brain metastases. Patients will receive standard imaging at baseline, including FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at the recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) three hours after unlabeled dose of MM-302. Integrated MR/PET imaging of the brain and whole body will be performed at two time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive subsequent doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (either in the brain or systemically) or unacceptable toxicity, whichever occurs soonest. MR brain imaging and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.

    Sentiment: Strong Buy

  • Reply to

    poison pill

    by markifeldman Apr 13, 2016 4:36 PM
    scistats scistats Apr 13, 2016 6:56 PM Flag

    Holders
    As of
    March 1, 2016, there were approximately 530 holders of record of our common stock. Additionally, shares of common stock are held by financial institutions
    as nominees for beneficial owners that are deposited into participant accounts at the
    Depository Trust Company, which are considered to be held of record by
    Cede & Co. and are included in the holders of record as one stockhold

  • Reply to

    poison pill

    by markifeldman Apr 13, 2016 4:36 PM
    scistats scistats Apr 13, 2016 5:05 PM Flag

    "The company, Athersys Inc. of Cleveland, licensed the rights from the University of Minnesota, where the stem cell was discovered by Dr. Catherine M. Verfaillie and colleagues, university and company officials said."

    Sentiment: Strong Buy

  • Reply to

    poison pill

    by markifeldman Apr 13, 2016 4:36 PM
    scistats scistats Apr 13, 2016 4:51 PM Flag

    Indeed, the great mystery of the lack of insider shares held at ye ol'Athersys.

    What about the subsidiaries? How do they affect:
    1. A hostile takeover/buyout attempt
    2. Your estimation of who in management actually owns how much of Athersys

    BJ said he was concerned about a buyout, but are you being told the whole story?
    Do you see stock options coming to management soon?
    Going private is an option, or merging with Pfizer like Icagen?

    SUBSIDIARIES OF ATHERSYS, INC.
    ABT Holding Company (formerly Athersys, Inc.) Delaware
    Advanced Biotherapeutics, Inc. Delaware
    Athersys Limited United Kingdom
    ReGenesys LLC Delaware
    ReGenesys BVBA Belgium
    ReGenesys EU NV Belgium

    Sentiment: Strong Buy

SNY
40.365-0.785(-1.91%)3:57 PMEDT